Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric C Polley

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Journal of the American Heart Association|July 17, 2025
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular RiskYihong Deng, Eric C Polley, Jeph Herrin, et al.
Breast Cancer Research : BCR|April 30, 2021
Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancerJuanjuan Gu, Eric C Polley, Max Denis, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Journal of the National Cancer Institute|February 10, 2015
Application of molecular profiling in clinical trials for advanced metastatic cancersShivaani Kummar, P Mickey Williams, Chih-Jian Lih, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Gynecologic Oncology|January 8, 2019
Cancer susceptibility gene mutations in type I and II endometrial cancerBeverly Long, Jenna Lilyquist, Amy Weaver, et al.
Journal of Virology|April 13, 2018
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the ProteasomeSekar Natesampillai, Nathan W Cummins, Zilin Nie, et al.
Human Mutation|May 23, 2020
Mutation prevalence tables for hereditary cancer derived from multigene panel testingSteven N Hart, Eric C Polley, Amal Yussuf, et al.
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Journal of the American Heart Association|July 17, 2025
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular RiskYihong Deng, Eric C Polley, Jeph Herrin, et al.
Breast Cancer Research : BCR|April 30, 2021
Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancerJuanjuan Gu, Eric C Polley, Max Denis, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Journal of the National Cancer Institute|February 10, 2015
Application of molecular profiling in clinical trials for advanced metastatic cancersShivaani Kummar, P Mickey Williams, Chih-Jian Lih, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Gynecologic Oncology|January 8, 2019
Cancer susceptibility gene mutations in type I and II endometrial cancerBeverly Long, Jenna Lilyquist, Amy Weaver, et al.
Journal of Virology|April 13, 2018
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the ProteasomeSekar Natesampillai, Nathan W Cummins, Zilin Nie, et al.
Human Mutation|May 23, 2020
Mutation prevalence tables for hereditary cancer derived from multigene panel testingSteven N Hart, Eric C Polley, Amal Yussuf, et al.
Pageof 12